BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
310.7 USD
-3.7 (-1.18%)
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While BIO.B has a great health rating, its profitability is only average at the moment. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO.B was profitable.
In the past year BIO.B had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.97%, BIO.B is in line with its industry, outperforming 53.45% of the companies in the same industry.
With a Return On Equity value of -10.03%, BIO.B perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.26%, BIO.B is in the better half of the industry, outperforming 62.07% of the companies in the same industry.
BIO.B had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 13.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B's Operating Margin of 10.27% is fine compared to the rest of the industry. BIO.B outperforms 70.69% of its industry peers.
In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
BIO.B's Gross Margin of 52.42% is fine compared to the rest of the industry. BIO.B outperforms 63.79% of its industry peers.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
BIO.B has an Altman-Z score of 3.42. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
BIO.B has a better Altman-Z score (3.42) than 62.07% of its industry peers.
BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.57, BIO.B is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
The Debt to Equity ratio of BIO.B (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.23
WACC9.97%
2.3 Liquidity
BIO.B has a Current Ratio of 5.44. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.44, BIO.B belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B has a Quick ratio of 3.94. This is in the better half of the industry: BIO.B outperforms 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.90%.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
The Revenue has decreased by -0.88% in the past year.
BIO.B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
Based on estimates for the next years, BIO.B will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.14, the valuation of BIO.B can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 70.69% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BIO.B to the average of the S&P500 Index (26.46), we can say BIO.B is valued inline with the index average.
BIO.B is valuated quite expensively with a Price/Forward Earnings ratio of 29.92.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 68.97% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (36.10), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.89 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.85
EPS Next 2Y0.36%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (11/17/2025, 8:04:00 PM)
310.7
-3.7 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change35.42%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap8.38B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (17.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.58%
PT rev (3m)-1.58%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)18.63%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)2.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 | ||
| P/S | 3.28 | ||
| P/FCF | 24.89 | ||
| P/OCF | 17.05 | ||
| P/B | 1.24 | ||
| P/tB | 1.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.38
Fwd EY3.34%
FCF(TTM)12.48
FCFY4.02%
OCF(TTM)18.22
OCFY5.87%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.85
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.42 |
F-Score5
WACC9.97%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y15.44%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
What is the valuation status of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 30.14 and the Price/Book (PB) ratio is 1.24.
What is the earnings growth outlook for BIO-RAD LABORATORIES -CL B?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES -CL B (BIO.B) is expected to decline by -1.94% in the next year.